Abstract 【Objective】 To investigate the relationship of serum levels of human cartilage glycoprotein 39 (YKL-40), homocysteine (Hcy), uric acid (UA), and brain-derived neurotrophic factor (BDNF) with cognitive function in patients with Parkinson's disease (PD).【Methods】 A total of 113 PD patients were enrolled. According to the presence or absence of cognitive impairment, they were divided into a cognitive impairment group (Group A, n=62) and a non-cognitive impairment group (Group B, n=51). Patients in Group A were further classified into a mild group (n=34), a moderate group (n=18), and a severe group (n=10) based on the severity of cognitive impairment. The serum levels of YKL-40, Hcy, UA, and BDNF were compared between Groups A and B and analyzed among sub-groups of patients with different degrees of cognitive impairment as well. The predictive value for cognitive impairment was analyzed, and the correlations between these serum indicators and the degree of cognitive impairment were further examined. 【Results】Serum YKL-40 and Hcy levels in Group A were significantly higher than those in Group B, whereas serum UA and BDNF levels were significantly lower than those in Group B (P<0.05). Receiver operating characteristic curve analysis showed that the optimal cutoff values YKL-40,Hcy,UA,BDNF for predicting cognitive impairment were 4.015 mg/mL, 24.930 μmol/L, 296.235 μmol/L, and 11.195 ng/mL (all P<0.05). In the severe subgroup, serum YKL-40 and Hcy levels were higher and UA and BDNF levels were lower than those in both mild and moderate subgroups (P<0.05). In the moderate subgroup, serum YKL-40 and Hcy levels were higher and UA and BDNF levels were lower than those in the mild subgroup (P<0.05). Correlation analysis showed that serum YKL-40 and Hcy levels were positively correlated with the degree of cognitive impairment (P<0.05), whereas serum UA and BDNF levels were negatively correlated with the degree of cognitive impairment (P<0.05). 【Conclusion】 PD patients with cognitive impairment exhibit notably elevated serum YKL-40 and Hcy levels as well as decreased serum UA and BDNF levels, all of which are closely related to the severity of cognitive impairment.
GAO Yuan,TIAN Feng. Correlation of Serum YKL-40, Hcy, UA, and BDNF Levels with Cognitive Function in Patients with Parkinson's Disease[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(1): 23-26.
[1] 宿瑞俊.免疫炎症与帕金森病发生关系的研究进展[J].山东医药,2020,60(31):112-115. [2] SHI G M, LI M H, YAN E, et al. Prognostic performance of serum YKL-40 for one-year clinical outcomes in acute ischemic stroke[J].Aging (Albany NY),2023,15(4):1199-1209. [3] 张家和,柯开富,施建生,等.血尿酸、Cys C及Hcy与老年帕金森病患者病程及疾病严重程度相关性分析[J].中国医药导报,2022,19(5):82-85. [4] 钟怡,王凯,申佩.血尿酸及血脂水平与帕金森病发病的相关性分析[J].医学临床研究,2022,39(8):1141-1143. [5] 张振学,王佳慧.认知矫正联合常规药物治疗双相情感障碍患者疗效及对TBIL、UA和BDNF的影响[J].中南医学科学杂志,2023,51(2):246-249. [6] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业. 中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,49(4):268-271. [7] 施宛盈,姚丽芬.帕金森病合并轻度认知损害研究新进展[J].中国临床神经科学,2020,28(2):229-234. [8] 张硕,高健,姜立刚.帕金森病患病率及相关因素的流行病学研究现状[J].吉林医药学院学报,2021,42(6):437-439. [9] BROSSERON F, MAASS A, KLEINEIDAM L, et al. Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer's disease: results from the DELCODE study[J].Alzheimers Res Ther,2023,15(1):13. [10] HUO L J, ZHENG Z W, LU X B, et al. Decreased peripheral BDNF levels and cognitive impairment in late-life schizophrenia[J].Front Psychiatry,2021,12:641278. [11] 陈浩,周培媚.YKL-40在炎症性疾病中的研究进展[J].四川医学,2022,43(4):392-396. [12] 孙妮,时晶,刘贵安. 血清EGF、YKL-40、SAA水平与帕金森病患者认知障碍的相关性分析[J].河北医学,2021,27(7):1090-1093. [13] TAHER Y, NATHEER M, MAJDAL H. The correlation between serum homocysteine level and parkinson's disease disability[J].Georgian Med News,2022,(331):36-41. [14] 陈红,郭太林.老年帕金森病患者血清同型半胱氨酸及血尿酸水平与认知功能障碍的相关性分析[J].中国医师杂志,2020,22(3):442-444. [15] 侯俊霞,叶林峰,欧鲤娴,等.帕金森病患者血清MIF、BDNF及尿AD7c-NTP表达水平与认知功能损伤的相关性[J].西部医学,2021,33(11):1665-1669.
2025, Vol. 42 
